Full Text
PCN101 COST-UTILITY ANALYSIS OF DASATINIB AS A SECOND-LINE TREATMENT IN THE CHRONIC PHASE OF CHRONIC MYELOID LEUKAEMIA IN RUSSIA

Abstract

Authors

S Kuznetzov LJ Mungapen Y Samyshkin DE Jakouloff U Sbarigia M van Baardewijk

Back to Volume 13, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×